Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced a fully underwritten $121 million equity raising comprising a pro-rata accelerated non-renounceable entitlement offer and placement to institutional investors.
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 Australian BiotechLatest Video
New Stories
-
ENA respiratory secures extension of US funding for novel prophylactic antiviral
September 8, 2024 - - Latest News -
Groups welcome wider access to shingles vaccine for immunocompromised patients
September 6, 2024 - - Latest News -
CSL announces sale of Wuhan plasma collection and fractionation operations
September 5, 2024 - - Latest News -
The 'Week in Review' Podcast - 6 September
September 5, 2024 - - Podcast -
Pfizer-backed initiative boosts Aboriginal and Torres Strait Islander pharmacy leadership
September 5, 2024 - - Latest News -
An increasingly busy ministerial agenda risks squeezing out other issues
September 5, 2024 - - Latest News -
Groups collaborate on the development of new opioid safety toolkit
September 5, 2024 - - Latest News